Naito Atsushi, Kagawa Yoshinori, Kawai Kenji, Takeno Atsushi, Takeda Yutaka, Ohtsuka Masahisa, Suzuki Yozo, Imasato Mitsunobu, Fujie Yujiro, Nakaba Hiroyuki, Akamatsu Hiroki, Murata Kohei
Dept. of Gastroenterological Surgery, Osaka Police Hospital.
Gan To Kagaku Ryoho. 2020 Feb;47(2):298-300.
A 71-year-old woman with advanced ascending colon cancer was admitted to our hospital. Abdominal computed tomography( CT)revealed locally advanced sigmoid colon cancer with suspected invasion of the liver and duodenum. The clinical stage of the disease was cT4bN3M1a, cStage Ⅳa, with wild-type RAS and UGT1A1 expression. An ileostomy was performed because of bowel obstruction. The patient received 6 courses of FOLFOXIRI plus bevacizumab(Bev). The only adverse event was Grade 3 neutropenia. Laparoscopic right hemicolectomy with lymph node dissection was performed. The pathological diagnosis was the absence of viable, Grade 3 carcinoma cells. This result suggested that preoperative FOLFOXIRI plus Bev chemotherapy is useful for the treatment of locally advanced colon cancer.
一名71岁的升结肠癌晚期女性入住我院。腹部计算机断层扫描(CT)显示局部晚期乙状结肠癌,怀疑侵犯肝脏和十二指肠。疾病的临床分期为cT4bN3M1a,c期Ⅳa,RAS和UGT1A1表达为野生型。由于肠梗阻进行了回肠造口术。患者接受了6个疗程的FOLFOXIRI联合贝伐单抗(Bev)治疗。唯一的不良事件是3级中性粒细胞减少。进行了腹腔镜右半结肠切除术并清扫淋巴结。病理诊断为无存活的3级癌细胞。这一结果表明术前FOLFOXIRI联合Bev化疗对局部晚期结肠癌的治疗有效。